-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, August 12 Recently, Yangtze River Haini Pharmaceuticals entered the administrative approval stage with imitation of azilsartan tablets submitted for production in Category 3, and is expected to be approved and deemed to have been reviewed
.
Azilsartan is an antihypertensive drug developed by Takeda, with global sales of approximately US$773 million in 2020
.
On June 8, 2021, Hengrui Pharmaceutical's Azilsartan tablets won the first domestic imitation, and Yangtze River Haini Pharmaceuticals will hit the second domestic product
.
.
Azilsartan is an antihypertensive drug developed by Takeda, with global sales of approximately US$773 million in 2020
.
On June 8, 2021, Hengrui Pharmaceutical's Azilsartan tablets won the first domestic imitation, and Yangtze River Haini Pharmaceuticals will hit the second domestic product
.
Azilsartan by Takeda developed an angiotensin II receptor blocker (ARB), in January 2012 approved in Japan for treatment of high blood pressure disease
.
According to data from Menet.
com, in 2020, Takeda’s Azilva’s global sales reached 82.
2 billion yen (approximately US$773 million at the 2020 average exchange rate)
.
.
According to data from Menet.
com, in 2020, Takeda’s Azilva’s global sales reached 82.
2 billion yen (approximately US$773 million at the 2020 average exchange rate)
.
Azilva global sales (unit: million yen)
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
At present, Takeda's Azilsartan tablets have not yet been approved for listing in China
.
Hengrui Medicine , Baiao medicine, Katherine Branch medicine, medicine and other Yangtze River Haynie four companies to submit three types of generic tablets azilsartan listing application, Shandong new era, Mogadishu Pharmaceutical, pharmaceutical and other Kaifeng 4 The company's product is in the BE test
.
.
Hengrui Medicine , Baiao medicine, Katherine Branch medicine, medicine and other Yangtze River Haynie four companies to submit three types of generic tablets azilsartan listing application, Shandong new era, Mogadishu Pharmaceutical, pharmaceutical and other Kaifeng 4 The company's product is in the BE test
.
List of Azilsartan Tablets Pending Approval Companies
Source: One-click search on Mi Nei.
com
com
Hengrui Medicine's Azilsartan tablets were approved as the first domestic imitation on June 8, 2021
.
Recently, the registration status of Azilsartan tablets of Yangtze River Haini Pharmaceutical Co.
, Ltd.
has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the second domestic company
.
.
Recently, the registration status of Azilsartan tablets of Yangtze River Haini Pharmaceutical Co.
, Ltd.
has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the second domestic company
.
Data source: Mi Neiwang database, NMPA
Medical Network News, August 12 Recently, Yangtze River Haini Pharmaceuticals entered the administrative approval stage with imitation of azilsartan tablets submitted for production in Category 3, and is expected to be approved and deemed to have been reviewed
.
Azilsartan is an antihypertensive drug developed by Takeda, with global sales of approximately US$773 million in 2020
.
On June 8, 2021, Hengrui Pharmaceutical's Azilsartan tablets won the first domestic imitation, and Yangtze River Haini Pharmaceuticals will hit the second domestic product
.
.
Azilsartan is an antihypertensive drug developed by Takeda, with global sales of approximately US$773 million in 2020
.
On June 8, 2021, Hengrui Pharmaceutical's Azilsartan tablets won the first domestic imitation, and Yangtze River Haini Pharmaceuticals will hit the second domestic product
.
Azilsartan by Takeda developed an angiotensin II receptor blocker (ARB), in January 2012 approved in Japan for treatment of high blood pressure disease
.
According to data from Menet.
com, in 2020, Takeda’s Azilva’s global sales reached 82.
2 billion yen (approximately US$773 million at the 2020 average exchange rate)
.
.
According to data from Menet.
com, in 2020, Takeda’s Azilva’s global sales reached 82.
2 billion yen (approximately US$773 million at the 2020 average exchange rate)
.
Azilva global sales (unit: million yen)
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
At present, Takeda's Azilsartan tablets have not yet been approved for listing in China
.
Hengrui Medicine , Baiao medicine, Katherine Branch medicine, medicine and other Yangtze River Haynie four companies to submit three types of generic tablets azilsartan listing application, Shandong new era, Mogadishu Pharmaceutical, pharmaceutical and other Kaifeng 4 The company's product is in the BE test
.
.
Hengrui Medicine , Baiao medicine, Katherine Branch medicine, medicine and other Yangtze River Haynie four companies to submit three types of generic tablets azilsartan listing application, Shandong new era, Mogadishu Pharmaceutical, pharmaceutical and other Kaifeng 4 The company's product is in the BE test
.
List of Azilsartan Tablets Pending Approval Companies
Source: One-click search on Mi Nei.
com
com
Hengrui Medicine's Azilsartan tablets were approved as the first domestic imitation on June 8, 2021
.
Recently, the registration status of Azilsartan tablets of Yangtze River Haini Pharmaceutical Co.
, Ltd.
has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the second domestic company
.
.
Recently, the registration status of Azilsartan tablets of Yangtze River Haini Pharmaceutical Co.
, Ltd.
has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the second domestic company
.
Data source: Mi Neiwang database, NMPA
Medical Network News, August 12 Recently, Yangtze River Haini Pharmaceuticals entered the administrative approval stage with imitation of azilsartan tablets submitted for production in Category 3, and is expected to be approved and deemed to have been reviewed
.
Azilsartan is an antihypertensive drug developed by Takeda, with global sales of approximately US$773 million in 2020
.
On June 8, 2021, Hengrui Pharmaceutical's Azilsartan tablets won the first domestic imitation, and Yangtze River Haini Pharmaceuticals will hit the second domestic product
.
.
Azilsartan is an antihypertensive drug developed by Takeda, with global sales of approximately US$773 million in 2020
.
On June 8, 2021, Hengrui Pharmaceutical's Azilsartan tablets won the first domestic imitation, and Yangtze River Haini Pharmaceuticals will hit the second domestic product
.
Azilsartan by Takeda developed an angiotensin II receptor blocker (ARB), in January 2012 approved in Japan for treatment of high blood pressure disease
.
According to data from Menet.
com, in 2020, Takeda’s Azilva’s global sales reached 82.
2 billion yen (approximately US$773 million at the 2020 average exchange rate)
.
Hypertension hypertension hypertension.
According to data from Menet.
com, in 2020, Takeda’s Azilva’s global sales reached 82.
2 billion yen (approximately US$773 million at the 2020 average exchange rate)
.
Azilva global sales (unit: million yen)
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
At present, Takeda's Azilsartan tablets have not yet been approved for listing in China
.
Hengrui Medicine , Baiao medicine, Katherine Branch medicine, medicine and other Yangtze River Haynie four companies to submit three types of generic tablets azilsartan listing application, Shandong new era, Mogadishu Pharmaceutical, pharmaceutical and other Kaifeng 4 The company's product is in the BE test
.
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise Enterprise.
Hengrui Medicine , Baiao medicine, Katherine Branch medicine, medicine and other Yangtze River Haynie four companies to submit three types of generic tablets azilsartan listing application, Shandong new era, Mogadishu Pharmaceutical, pharmaceutical and other Kaifeng 4 The company's product is in the BE test
.
List of Azilsartan Tablets Pending Approval Companies
Source: One-click search on Mi Nei.
com
com
Hengrui Medicine's Azilsartan tablets were approved as the first domestic imitation on June 8, 2021
.
Recently, the registration status of Azilsartan tablets of Yangtze River Haini Pharmaceutical Co.
, Ltd.
has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the second domestic company
.
.
Recently, the registration status of Azilsartan tablets of Yangtze River Haini Pharmaceutical Co.
, Ltd.
has been changed to "under approval".
If it is successfully approved, it will be deemed to have been reviewed and become the second domestic company
.
Data source: Mi Neiwang database, NMPA
